A Brief Update on Angiotensin & Aldosterone Inhibition in COVID-19
www.pulmccm.org
Jon-Emile S. Kenny MD [@heart_lung] “We’re on a road to nowhere ...” -David Byrne Background In early March of this year, Fang and colleagues published a letter noting that patients with diabetes and/or hypertension treated with ACE inhibitors or angiotensin II type-1 receptor blockers [i.e. ARBs] increase their expression of the ACE2 enzyme. Parenthetically, they also stated that ACE2 is upregulated by thiazolidinediones and ibuprofen. They then speculated that because SARS-CoV2 gains intracellular entry via ACE2 binding, the association between diabetes and hypertension and adverse COVID-19 outcome is, potentially, mediated by medication-induced ACE2 over-expression.
A Brief Update on Angiotensin & Aldosterone Inhibition in COVID-19
A Brief Update on Angiotensin & Aldosterone…
A Brief Update on Angiotensin & Aldosterone Inhibition in COVID-19
Jon-Emile S. Kenny MD [@heart_lung] “We’re on a road to nowhere ...” -David Byrne Background In early March of this year, Fang and colleagues published a letter noting that patients with diabetes and/or hypertension treated with ACE inhibitors or angiotensin II type-1 receptor blockers [i.e. ARBs] increase their expression of the ACE2 enzyme. Parenthetically, they also stated that ACE2 is upregulated by thiazolidinediones and ibuprofen. They then speculated that because SARS-CoV2 gains intracellular entry via ACE2 binding, the association between diabetes and hypertension and adverse COVID-19 outcome is, potentially, mediated by medication-induced ACE2 over-expression.